Research Report Details
Subscribe for industry reports
Author / Researcher : Global Markets Direct
Number Of Pages/Tabs : 72
Number Of Charts : N/A
Published Date : 04/27/2016
Industries : Multiple
Countries : All
Quality Score : 5
Have a question about this report?
24/7 Research Support
Talk to Zursh Analyst
+1 858 522 9998 or Email Us
The report provides comprehensive information on the therapeutics under development for Narcolepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Additionally, the report provides an overview of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications.
The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information.
Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Narcolepsy - The report reviews pipeline therapeutics for Narcolepsy by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Narcolepsy therapeutics and enlists all their major and minor projects - The report assesses Narcolepsy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Narcolepsy Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Narcolepsy - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Narcolepsy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Narcolepsy Overview 8 Therapeutics Development 9 Pipeline Products for Narcolepsy - Overview 9 Pipeline Products for Narcolepsy - Comparative Analysis 10 Narcolepsy - Therapeutics under Development by Companies 11 Narcolepsy - Therapeutics under Investigation by Universities/Institutes 12 Narcolepsy - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Narcolepsy - Products under Development by Companies 16 Narcolepsy - Products under Investigation by Universities/Institutes 17 Narcolepsy - Companies Involved in Therapeutics Development 18 Bioprojet SCR 18 Evotec AG 19 Flamel Technologies S.A. 20 H.A.C. Pharma 21 Jazz Pharmaceuticals Plc 22 NLS Pharma Group 23 Sanofi 24 SK Biopharmaceuticals Co., Ltd. 25 Taisho Pharmaceutical Holdings Co., Ltd. 26 Theranexus SAS 27 Narcolepsy - Therapeutics Assessment 28 Assessment by Monotherapy Products 28 Assessment by Combination Products 29 Assessment by Target 30 Assessment by Mechanism of Action 32 Assessment by Route of Administration 34 Assessment by Molecule Type 35 Drug Profiles 36 (modafinil + THN-02) - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 arbaclofen - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 JZP-386 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 mazindol - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 mazindol - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 NLS-3 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Pentylenetetrazol - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 pitolisant - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 SAR-110068 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 SKL-N05 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Small Molecules to Agonize Orexin Receptor 2 for Nacrcolepsy - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Small Molecules to Agonize Orexin Receptor for EDS and Narcolepsy - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 sodium oxybate - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 sodium oxybate - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 TS-091 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Narcolepsy - Recent Pipeline Updates 57 Narcolepsy - Dormant Projects 62 Narcolepsy - Discontinued Products 63 Narcolepsy - Product Development Milestones 64 Featured News & Press Releases 64 Mar 31, 2016: Flamel Technologies Files Special Protocol Assessment for Once Nightly Sodium Oxybate 64 Mar 30, 2016: Theranexus: Preclinical Results Published in the Specialist Medical Journal Sleep 64 Nov 20, 2015: Narcolepsy treatment recommended for approval 65 Jul 15, 2015: Theranexus Success of phase 1 trial on the safety of a new treatment of narcolepsy and launch of efficacy studies 65 Jun 04, 2015: Jazz Pharmaceuticals to Present Abstracts from Ongoing Evaluations of Xyrem(sodium oxybate) at SLEEP 2015 66 May 07, 2015: Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update 67 Dec 19, 2014: Flamel Technologies Announces Positive Results of a Second Clinical Trial With Micropump Sodium Oxybate 67 Dec 09, 2014: Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update 68 Dec 02, 2014: Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Trial of Xyrem (Sodium Oxybate) In Children And Adolescents Who Have Narcolepsy With Cataplexy 69 Jul 21, 2014: Jazz Pharmaceuticals and Concert Pharmaceuticals Provide a Phase 1 Clinical Trial Update on JZP-386 69 Appendix 71 Methodology 71 Coverage 71 Secondary Research 71 Primary Research 71 Expert Panel Validation 71 Contact Us 71 Disclaimer 72 List of Tables Number of Products under Development for Narcolepsy, H1 2016 9 Number of Products under Development for Narcolepsy - Comparative Analysis, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Number of Products under Investigation by Universities/Institutes, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Development, H1 2016 15 Products under Development by Companies, H1 2016 16 Products under Investigation by Universities/Institutes, H1 2016 17 Narcolepsy - Pipeline by Bioprojet SCR, H1 2016 18 Narcolepsy - Pipeline by Evotec AG, H1 2016 19 Narcolepsy - Pipeline by Flamel Technologies S.A., H1 2016 20 Narcolepsy - Pipeline by H.A.C. Pharma, H1 2016 21 Narcolepsy - Pipeline by Jazz Pharmaceuticals Plc, H1 2016 22 Narcolepsy - Pipeline by NLS Pharma Group, H1 2016 23 Narcolepsy - Pipeline by Sanofi, H1 2016 24 Narcolepsy - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 25 Narcolepsy - Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H1 2016 26 Narcolepsy - Pipeline by Theranexus SAS, H1 2016 27 Assessment by Monotherapy Products, H1 2016 28 Assessment by Combination Products, H1 2016 29 Number of Products by Stage and Target, H1 2016 31 Number of Products by Stage and Mechanism of Action, H1 2016 33 Number of Products by Stage and Route of Administration, H1 2016 34 Number of Products by Stage and Molecule Type, H1 2016 35 Narcolepsy Therapeutics - Recent Pipeline Updates, H1 2016 57 Narcolepsy - Dormant Projects, H1 2016 62 Narcolepsy - Discontinued Products, H1 2016 63 List of Figures Number of Products under Development for Narcolepsy, H1 2016 9 Number of Products under Development for Narcolepsy - Comparative Analysis, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Products, H1 2016 15 Assessment by Monotherapy Products, H1 2016 28 Number of Products by Targets, H1 2016 30 Number of Products by Stage and Targets, H1 2016 30 Number of Products by Mechanism of Actions, H1 2016 32 Number of Products by Stage and Mechanism of Actions, H1 2016 32 Number of Products by Stage and Routes of Administration, H1 2016 34 Number of Products by Stage and Molecule Types, H1 2016 35
Summary of Source & MethodologyTrue
Global Markets Direct follows the highest standards when conducting primary and secondary research, including thousands of interviews with senior executives every year, to enable clients to make sound business decisions for their company in complete confidence. 1. 1 million-strong stakeholder group, plus 25,000 interviews annually 2. Rigorous checks on over 25,000 public and proprietary sources 3. Data modeled and forecasted with gold-standard methodology 4. Updated in real time 5. Expert insights and critical analysis from 700 experienced researchers and analysts If you would like to request the complete research methodology of this report or any additional information, please send us an email to firstname.lastname@example.org
Download additional documents & original sources used by researcher/publisher to support the report dataDownload Documents No documents available for download
Zursh quality control analysts have developed a nice rating algorithm to independently and objectively evaluate the quality of this report.